Plasma-derived nanoparticles
AssigneeThe Heart Research Institute Ltd.
InventorsMiguel Angelo CORREIA DOS SANTOS, Elysse FILIPE, Praveesuda LORWATTANAPONGSA, Marcela BILEK, Steven Garry WISE
Life of this patent
Estimating the term…
Abstract
This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.
Claims21
1-38. (canceled)
A conjugate comprising:
- a nanoparticulate polymer with a mean diameter of 1 nm to 50 nm and formed from a plasma comprising at least one monomer selected from the group consisting of:
- an alkene, an alkyne, a cycloalkene, a cycloalkyne, and mixtures thereof;
- or an aggregate comprising two or more of the nanoparticulate polymers, wherein the aggregate has a mean diameter of 5 nm to 500 nm;
- and
- at least one second species.
A pharmaceutical composition comprising:
- a nanoparticulate polymer with a mean diameter of 1 nm to 50 nm and formed from a plasma comprising at least one monomer selected from the group consisting of:
- an alkene, an alkyne, a cycloalkene, a cycloalkyne, and mixtures thereof;
- or an aggregate comprising two or more of the nanoparticulate polymers, wherein the aggregate has a mean diameter of 5 nm to 500 nm;
- and
- at least one second species,
- and a pharmaceutically acceptable carrier, excipient, or binder.
A method of treating a subject suffering from, susceptible to, or displaying one or more symptoms of a disease, disorder, or condition, the method comprising a step of administering:
- i) a conjugate comprising:
- a nanoparticulate polymer with a mean diameter of 1 nm to 50 nm and formed from a plasma comprising at least one monomer selected from the group consisting of:
- an alkene, an alkyne, a cycloalkene, a cycloalkyne, and mixtures thereof;
- or an aggregate comprising two or more of the nanoparticulate polymers, wherein the aggregate has a mean diameter of 5 nm to 500 nm;
- and
- at least one second species, or
- ii) a pharmaceutical composition comprising the conjugate of i) and a pharmaceutically acceptable carrier, excipient, or binder,
- to the subject.
Dependencies are inferred from the claim text.